Melrilimab (CNTO7160 / GSK-3772847) is a monoclonal antibody targeting IL-33R which underwent a phase I clinical trial in patients with asthma, AD and healthy individuals. This evidence concerns the gene IL1RL1 and Alzheimer disease.